Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 02/03/23
Jasper Therapeutics to Host Investor Conference Call and Webcast on January 31, 2023GlobeNewsWire • 01/30/23
Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 01/27/23
Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common StockGlobeNewsWire • 01/25/23
Jasper Therapeutics Announces New Positive Briquilimab Data to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTRGlobeNewsWire • 01/13/23
Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, Including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare DiseasesGlobeNewsWire • 01/10/23
Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as a Conditioning Treatment for Patients Prior to Receiving a Stem Cell TransplantGlobeNewsWire • 01/04/23
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta ThalassemiaGlobeNewsWire • 01/03/23
Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 11/10/22
Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual MeetingGlobeNewsWire • 09/26/22
Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, a novel monoclonal antibody targeting CD117, in the treatment of patients with severe combined immunodeficiency (SCID) undergoing allogeneic hematopoietic stem cell transplantGlobeNewsWire • 09/15/22
Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 08/12/22
All You Need to Know About Jasper Therapeutics, Inc. (JSPR) Rating Upgrade to BuyZacks Investment Research • 07/15/22
Jasper Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines SymposiumGlobeNewsWire • 06/23/22
Jasper Therapeutics to Participate in the William Blair 42nd Annual Growth Stock ConferenceGlobeNewsWire • 06/07/22
Jasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022GlobeNewsWire • 06/06/22
Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi AnemiaGlobeNewsWire • 05/17/22
Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 05/12/22